Organisation paid for research Program year 2024 Source: CMS Open Payments

Keystone Research Ltd

Neither a doctor nor a teaching hospital

Research payments

$2,122,071

415 payments

Through program year 2024, Keystone Research Ltd is reported as receiving $2,122,071 in research payments, across 415 payments.

By program year

6 rows
Year Kind Amount Payments
2024 Research $1,710 2
2023 Research $197,331 36
2022 Research $156,559 13
2021 Research $245,690 119
2020 Research $441,844 84
2019 Research $1,078,938 161

Breakdown

Who paid Research payments · program years 2019–2024
  1. Allergan Inc. $1,108,286 149 payments
  2. Ocular Therapeutix, Inc. $289,845 20 payments
  3. AbbVie, Inc. $276,352 25 payments
  4. Alcon Research LLC $201,506 196 payments
  5. Novartis Pharmaceuticals Corporation $141,227 4 payments
  6. Sun Pharmaceutical Industries Inc. $43,148 7 payments
  7. Ivantis, Inc $35,087 8 payments
  8. Kala Pharmaceuticals, Inc. $26,620 6 payments
Studies the money was for Research payments · program years 2019–2024
  1. Multicenter Double Masked Randomized Vehicle-Controlled Parallel-Group study of AGN-190584 for Participants with Presbyopia $521,646 9 payments
  2. Long-term Safety and Efficacy Extension Trial of Bimatoprost SR $253,680 22 payments
  3. A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients with Open-Angle Glaucoma or Ocular Hypertension $214,105 61 payments
  4. The Efficacy and Safety of Bimatoprost SR in Patients With Open-angle Glaucoma or Ocular Hypertension $156,882 30 payments
  5. A Prospective Multicenter Open Label Study to Evaluate the Safety Tolerability and Efficacy of OTX TIC Implant in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension $102,720 11 payments
  6. Open Label Study to Evaluate the Safety, Tolerability and Efficacy of OTX-TIC (Travoprost) Implant in Subjects with Primary Open-Angle Glaucoma or Ocular Hypertension $93,054 1 payment
  7. An Eighteen-Month, Two-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due to MacUlar Edema Secondary to Branch Retinal Vein Occlusi $81,886 1 payment
  8. A multicenter, open-label, single arm study in patients with open angle glaucoma or ocular hypertension who have not had previous laser trabeculoplasty treatment $77,095 16 payments
  9. Exploratory study comparing Visual performance between AcrySof IQ and Tecnis Monofocal(Exploratory study comparing Visual performance between AcrySof IQ and Tecnis Monofocal) $68,579 33 payments
  10. Post Approval Study of the AcrySof IQ ReSTOR Toric IOL $52,100 101 payments
What the money was spent on Research payments · program years 2019–2024
  1. Other $43,148 7 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record